Kyoto University researchers have regenerated neural stem cells in an adult mouse and improved its cognitive function through its method, dubbed "iPaD."
The test results were equivalent to turning a 60-year-old-human's neural stem cells into those of a teenager.
However, there are challenges in applying the procedure to humans because the mouse’s genetic engineering involved using a virus to inject the genes into the brain.
The research team’s leader, visiting professor Ryoichiro Kageyama, said they would continue to see if the procedure can be applied to humans.
The team will now test its iPaD method on marmosets to determine if its applicability to primates.
The ability to multiply embryonic neural stem cells to increase the number of nerve cells weakens with age. That, in turn, results in reduced cognitive function.
The iPaD method maximizes the activation of the neural stem cells by combining the infant mice’s most active genes with a restraining function of the adult mice’s most active genes.
The engineered neural stem cells in an adult mouse became more active with the neural stem cells continuing to multiply for about three months.
|Consequently, the adult mouse improved its cognitive function with the increase in neural stem cell multiplication.


Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Oil Prices Slip as U.S.–Iran Talks Ease Supply Disruption Fears
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Instagram Outage Disrupts Thousands of U.S. Users
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Australia’s December Trade Surplus Expands but Falls Short of Expectations
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 



